drugset
drugset / Trial / NCT02613650

A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

NCT02613650 ↗

Phase 1 Completed 25 enrolled University of Utah Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination

Timeline

Start
2016-08-19
Primary completion
2022-11-23
Completion
2022-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Binimetinib Small molecule 30 mg Oral
Subject Binimetinib Small molecule 45 mg Oral
Subject Irinotecan Small molecule 180 mg/m2 Intravenous
Subject fluorouracil Small molecule 2400 mg/m2 —

Indications

colorectal cancer